139 related articles for article (PubMed ID: 12771527)
1. Multidrug resistance in prostate cancer.
van Brussel JP; Mickisch GH
Onkologie; 2003 Apr; 26(2):175-81. PubMed ID: 12771527
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins.
Sánchez C; Mercado A; Contreras HR; Mendoza P; Cabezas J; Acevedo C; Huidobro C; Castellón EA
Prostate; 2011 Dec; 71(16):1810-7. PubMed ID: 21480311
[TBL] [Abstract][Full Text] [Related]
3. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
Sánchez C; Mendoza P; Contreras HR; Vergara J; McCubrey JA; Huidobro C; Castellón EA
Prostate; 2009 Sep; 69(13):1448-59. PubMed ID: 19496068
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein.
Wu F; Shao ZY; Zhai BJ; Zhao CL; Shen DM
Ultrasound Med Biol; 2011 Jan; 37(1):151-9. PubMed ID: 21084157
[TBL] [Abstract][Full Text] [Related]
6. Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Xiao Z; Ding N; Xiao G; Wang S; Wu Y; Tang L
Anat Rec (Hoboken); 2012 Dec; 295(12):2122-8. PubMed ID: 22907845
[TBL] [Abstract][Full Text] [Related]
7. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
8. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
Wang G; Rong J; Zhou Z; Duo J
Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
[TBL] [Abstract][Full Text] [Related]
9. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
van Brussel JP; Oomen MA; Vossebeld PJ; Wiemer EA; Sonneveld P; Mickisch GH
BJU Int; 2004 Jun; 93(9):1333-8. PubMed ID: 15180633
[TBL] [Abstract][Full Text] [Related]
10. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
11. [Reversal of multidrug resistance of gastric cancer cells by down-regulation of CIAPIN1 with CIAPIN1 siRNA].
Li X; Fan R; Zou X; Hong L; Gao L; Jin H; Du R; He L; Xia L; Fan D
Mol Biol (Mosk); 2008; 42(1):102-9. PubMed ID: 18389626
[TBL] [Abstract][Full Text] [Related]
12. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.
Citti A; Boldrini R; Inserra A; Alisi A; Pessolano R; Mastronuzzi A; Zin A; De Sio L; Rosolen A; Locatelli F; Fruci D
Int J Oncol; 2012 Jul; 41(1):117-24. PubMed ID: 22504834
[TBL] [Abstract][Full Text] [Related]
13. Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
Southgate TD; Garside E; Margison GP; Fairbairn LJ
J Gene Med; 2006 Aug; 8(8):972-9. PubMed ID: 16733832
[TBL] [Abstract][Full Text] [Related]
14. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.
Zhang D; Fan D
Future Oncol; 2010 Apr; 6(4):527-37. PubMed ID: 20373867
[TBL] [Abstract][Full Text] [Related]
15. Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro.
Lo YL; Wang W
Chem Biol Interact; 2013 Oct; 205(3):188-97. PubMed ID: 23867903
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
18. Modulation of multidrug resistance: a paradigm for translational clinical research.
Sikic BI
Oncology (Williston Park); 1999 May; 13(5A):183-7. PubMed ID: 10370927
[TBL] [Abstract][Full Text] [Related]
19. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.
Zahedi P; De Souza R; Huynh L; Piquette-Miller M; Allen C
Mol Pharm; 2011 Feb; 8(1):260-9. PubMed ID: 21166459
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of MDR-1 by HOXC6 in multidrug-resistant cells.
Kim KJ; Moon SM; Kim SA; Kang KW; Yoon JH; Ahn SG
Oncogene; 2013 Jul; 32(28):3339-49. PubMed ID: 22907429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
